Pneumococcal conjugate vaccines (PCV) have been widely used in high-income countries for more than a decade, resulting in a dramatic reduction in pneumococcal disease caused by vaccine serotypes. PCV has been included in Turkey’s National Immunization Programme since 2009 with PCV7 and continued with PCV13 from 2011. We presented a three-month-old infant who developed mastoiditis secondary to S. pneumoniae serotype 19A after acute otitis media.
All Keywords
【저자키워드】 acute otitis media, mastoiditis, pneumococcal conjugate vaccine, serotype 19A,
【저자키워드】 acute otitis media, mastoiditis, pneumococcal conjugate vaccine, serotype 19A,